SIGA Technologies Inc

Research SIGA Technologies Inc (SIGA) on Bullrun: market cap USD 218.41M, dividend yield 19.6%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 218.41M; dividend yield is 19.6%.

Peer valuation comparison

Latest dividend yield is 19.61% versus a Healthcare sector median of 2.11% (829.4% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 94.57MUSD 23.28MUSD 43.12M68.6%0.32USD 154.97MUSD 595.17KUSD 198.82M
FY2024USD 138.72MUSD 59.21MUSD 48.72M77.4%0.82USD 155.40MUSD 546.82KUSD 215.80M
FY2023USD 139.92MUSD 68.07Mn/a87.3%0.95USD 150.15MUSD 564.01KUSD 196.86M
FY2022USD 110.78MUSD 33.90Mn/a90.6%0.46USD 98.79MUSD 507.14KUSD 170.16M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 218.41Mn/a19.7%0.6
20252025-12-31USD 437.55M19.19.8%0.6
20242024-12-31USD 429.14M7.210.0%0.6
20232023-12-29USD 398.11Mn/a8.0%0.45
20222022-12-30USD 537.46M5.16.1%0.45
20212021-12-31USD 553.05M8.2n/an/a

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.6 USD, yield 19.6%.

YearDividends/share
FY20250.6 USD
FY20240.6 USD
FY20230.45 USD
FY20220.45 USD

About SIGA Technologies Inc

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is SIGA Technologies Inc's market cap?

SIGA Technologies Inc's market capitalization is USD 218.41M.

Does SIGA Technologies Inc pay a dividend?

SIGA Technologies Inc has a dividend yield of 19.6%.

What does SIGA Technologies Inc do?

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.